We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.89%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.82B
AUM Growth
+$296M
Cap. Flow
+$80.3M
Cap. Flow %
4.42%
Top 10 Hldgs %
36.79%
Holding
155
New
17
Increased
81
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$21.6M
2
HUM icon
Humana
HUM
+$21.3M
3
TDOC icon
Teladoc Health
TDOC
+$18.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.4M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$9.38M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$56M
2
AMGN icon
Amgen
AMGN
+$5.81M
3
BIIB icon
Biogen
BIIB
+$5.29M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$5.16M
5
MGNX icon
MacroGenics
MGNX
+$4.78M

Sector Composition

Rank Sector Weight
1 Healthcare 91.35%
2 Industrials 1.12%
3 Technology 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
1
Align Technology
ALGN
$12.7B
$95.2M 5.24%
334,679
+23,884
+8% +$5.7M
ISRG icon
2
Intuitive Surgical
ISRG
$122B
$86.2M 4.74%
452,997
+36,606
+9% +$6.51M
ABT icon
3
Abbott
ABT
$175B
$83.2M 4.58%
1,040,587
+64,136
+7% +$4.77M
ILMN icon
4
Illumina
ILMN
$28.2B
$80.1M 4.41%
264,911
+5,965
+2% +$1.74M
TDOC icon
5
Teladoc Health
TDOC
$1.7B
$76.4M 4.2%
1,374,294
+300,455
+28% +$18.3M
ELV icon
6
Elevance Health
ELV
$80.9B
$73.2M 4.03%
255,017
+22,357
+10% +$6.47M
DHR icon
7
Danaher
DHR
$144B
$45.1M 2.48%
385,532
+10,025
+3% +$1.03M
MDT icon
8
Medtronic
MDT
$106B
$44.7M 2.46%
490,906
-5,540
-1% -$496K
BSX icon
9
Boston Scientific
BSX
$65.4B
$44M 2.42%
1,147,487
+90,598
+9% +$3.46M
HUM icon
10
Humana
HUM
$48B
$40.6M 2.23%
152,477
+73,817
+94% +$21.3M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.5B
$38.2M 2.1%
267,438
+6,790
+3% +$886K
BMY icon
12
Bristol-Myers Squibb
BMY
$124B
$33.2M 1.83%
695,824
+209,000
+43% +$10.4M
UNH icon
13
UnitedHealth
UNH
$387B
$32.8M 1.81%
132,837
+1
+0% +$255
BDX icon
14
Becton Dickinson
BDX
$43.6B
$32.2M 1.77%
132,196
+7,277
+6% +$1.72M
EW icon
15
Edwards Lifesciences
EW
$49.4B
$31M 1.7%
485,736
+12,345
+3% +$705K
SYK icon
16
Stryker
SYK
$123B
$29.4M 1.62%
148,900
-1,934
-1% -$348K
WCG
17
DELISTED
Wellcare Health Plans, Inc.
WCG
$29M 1.59%
107,419
+24,215
+29% +$6.26M
CI icon
18
Cigna
CI
$74.5B
$26.6M 1.47%
165,657
+32
+0% +$5.84K
QGEN icon
19
Qiagen
QGEN
$8.49B
$25.1M 1.38%
582,048
+171,537
+42% +$6.9M
ALNY icon
20
Alnylam Pharmaceuticals
ALNY
$35.7B
$25M 1.37%
267,305
+42,920
+19% +$3.59M
IONS icon
21
Ionis Pharmaceuticals
IONS
$8.99B
$24.6M 1.35%
302,643
-79,945
-21% -$5.16M
BAX icon
22
Baxter International
BAX
$11.7B
$23.8M 1.31%
293,174
+38,631
+15% +$2.81M
ALXN
23
DELISTED
Alexion Pharmaceuticals
ALXN
$23.1M 1.27%
171,150
+15,470
+10% +$1.92M
VRTX icon
24
Vertex Pharmaceuticals
VRTX
$123B
$21.5M 1.18%
116,989
+2,289
+2% +$423K
HRC
25
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$21.5M 1.18%
203,088
-1,920
-0.9% -$193K
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2019 Portfolio in Review

As of Q1 2019, Bellevue Group held 155 positions worth $1.82B, up 19% from $1.52B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group deployed $80.3M of net new capital in Q1 2019, opening 17 new positions and adding to 81 existing holdings. Its largest new stake was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Celgene Corp, an estimated $56M trimmed.

  • Bellevue Group's largest Q1 2019 buy was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.
  • Bellevue Group added most to Evolent Health in Q1 2019, an estimated $21.6M increase.
  • Bellevue Group's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $56M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q1 2019, selling an estimated $3.91M.
  • Bellevue Group's ten largest holdings make up 37% of its $1.82B portfolio in Q1 2019.
  • Bellevue Group opened 17 new positions and closed 18 in Q1 2019.
  • Bellevue Group's portfolio value rose 19% quarter-over-quarter to $1.82B.

Based on Bellevue Group's 13F filing for Q1 2019, filed 15 May 2019.